Tosatoxumab

Tosatoxumab (AR-301; KBSA301) is a human immunoglobulin G1 monoclonal antibody that specifically neutralizes alpha-toxin (alpha-hemolysin; Hla) of S. aureus. Tosatoxumab binds to an N-terminal epitope of alpha-toxin, thereby preventing functional toxin pore oligomerisation. Tosatoxumab has the potential for passive immunotherapy in the S. aureus pneumonia as an adjunctive therapy to standard antibiotic agent. Recommend Isotope Control: Human IgG1 lambda1, Isotype Control (HY-P99992) [1][2].

Product Specifications

CAS Number

[1374419-41-6]

Product Name Alternative

KBSA301; AR-301

UNSPSC

12352203

Target

Antibiotic; Bacterial

Type

Inhibitory Antibodies

Related Pathways

Anti-infection

Applications

COVID-19-immunoregulation

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/tosatoxumab.html

Purity

95.00

Solubility

H2O

Smiles

[Tosatoxumab]

Molecular Weight

(144.92 kDa)

References & Citations

[1]Bruno François, et al. Safety and tolerability of a single administration of AR-301, a human monoclonal antibody, in ICU patients with severe pneumonia caused by Staphylococcus aureus: first-in-human trial. Intensive Care Med. 2018 Nov;44 (11) :1787-1796.|[2]Philippe Vignon, et al. New Agents in Development for Sepsis: Any Reason for Hope? Drugs. 2020 Nov;80 (17) :1751-1761.|[3]Lugovskoy, A. A., et al., (2012) . 7th annual European Antibody Congress 2011: November 29-December 1, 2011, Geneva, Switzerland. mAbs, 4 (2), 134–152.